Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Danielle Lienard"'
Autor:
Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, Mélanie Delaunoy, Hakim El Housni, Gil Awada, Julia Katharina Schwarze, Marleen Keyaerts, Hendrik Everaert, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-13 (2019)
Abstract Background Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the
Externí odkaz:
https://doaj.org/article/8d5fc9238e2c429db072e48b95d79760
Publikováno v:
Melanoma Research. 29:95-98
The combination of BRAF and MEK inhibitors is a standard therapeutic option for patients with metastatic melanoma with BRAF-mutated tumors. This type of targeted therapy improved patient survival, having a manageable toxicity profile. Nevertheless, p
Autor:
Pierre Heimann, Max Schreuer, Simon Planken, Bart Neyns, Mélanie Delaunoy, Teofila Seremet, Hakim El Housni, Yanina Jansen, Véronique Del Marmol, Danielle Lienard
Publikováno v:
Melanoma Research. 28:65-70
Anti-programmed death 1 (PD-1) monoclonal antibodies improve the survival of metastatic melanoma patients. Predictive or monitoring biomarkers for response to this therapy could improve the clinical management of these patients. To date, no establish
Autor:
Hendrik Everaert, Danielle Lienard, Bart Neyns, Gil Awada, Simon Planken, Marleen Keyaerts, Hakim El Housni, Véronique Del Marmol, Pierre Heimann, Hassane Njimi, Mélanie Delaunoy, Julia Katharina Schwarze, Teofila Seremet, Yanina Jansen
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-13 (2019)
Journal of translational medicine, 17 (1
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-13 (2019)
Journal of translational medicine, 17 (1
Background: Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinica
Autor:
Gwendoline Diet, Clément Lenoir, Margot Fontaine, Lucas Boussingault, Carmen Orte Cano, Lyna Mtimet, Danielle Liénard, Dilara Sanak, Florine Moulart, Dana Bernardi, Anne-Laure Trepant, Javiera Perez-Anker, Susana Puig, Josep Malvehy, Elisa Cinotti, Linda Tognetti, Pietro Rubegni, Jean-Luc Perrot, Véronique Del Marmol, Mariano Suppa
Publikováno v:
Diagnostics, Vol 14, Iss 14, p 1562 (2024)
Extramammary Paget disease (EMPD) is an uncommon adenocarcinoma of apocrine gland-rich areas, presenting significant diagnostic challenges due to its nonspecific clinical appearance and frequent misidentification as benign, inflammatory skin conditio
Externí odkaz:
https://doaj.org/article/41aed8492bdc4848930176188749be1e
Autor:
Véronique Del Marmol, Danielle Lienard, Laura Vandeweerd, Teofila Seremet, Yanina Jansen, Simon Planken, Bart Neyns, Julia Katharina Schwarze, Ioannis Tsechelidis, Robbe Van den Begin
Publikováno v:
Melanoma research. 29(1)
Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint receptors (pembrolizumab, nivolumab, ipilimumab, or the combination of nivolumab with ipilimumab) are approved treatmen
Autor:
Danielle Lienard, Frederik Vandenbroucke, Hendrik Everaert, Stephanie Du Four, Véronique Del Marmol, Isabelle Salmon, Sofie Wilgenhof, Bart Neyns
Publikováno v:
Vrije Universiteit Brussel
Ipilimumab, a CTLA-4-blocking monoclonal antibody, improved the overall survival (OS) of advanced melanoma patients treated in prospective clinical trials. We here report a study on the outcome of patients with pretreated advanced melanoma offered ip
Autor:
Danielle Lienard, Kris Thielemans, Max Schreuer, Kelly Schats, Nicolas van Baren, Véronique Del Marmol, Tim De Meyer, Pierre Coulie, Teofila Seremet, Wim Van Criekinge, Sofie Wilgenhof, Yanina Jansen, Bart Neyns, Mark M. Kockx, Alexander Koch
Publikováno v:
JOURNAL OF TRANSLATIONAL MEDICINE
Journal of Translational Medicine, Vol. 14, no.1, p. 232 (2016)
Journal of translational medicine, 14 (1
Journal of Translational Medicine
Journal of Translational Medicine, Vol. 14, no.1, p. 232 (2016)
Journal of translational medicine, 14 (1
Journal of Translational Medicine
Background: Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10-15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing individualized treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2613ac01611ad9e86e71945900a15d96
https://hdl.handle.net/1854/LU-8516962
https://hdl.handle.net/1854/LU-8516962
Autor:
José Thomas, Marna G. Bouwhuis, Ghanem Elias Ghanem, Wim H. J. Kruit, Konstantin Stoitchkov, Poulam M. Patel, Veronique Cocquyt, A.M.M. Eggermont, Danielle Lienard, Stefan Suciu, François Sales
Publikováno v:
European Journal of Cancer, 47(3), 361-368. Elsevier Ltd.
S100B is a prognostic factor for melanoma as elevated levels correlate with disease progression and poor outcome. We determined its prognostic value based on updated information using serial determinations in stage IIb/III melanoma patients. 211 Pati
Autor:
Danielle Lienard, Yannick Zaugg, Luc Bron, Daniel E. Speiser, Suzanne Salvi, Jean-Paul Rivals, Pedro Romero, Cyril Cuffel, Philippe Monnier, Walter Seelentag, Donata Rimoldi
Publikováno v:
International Journal of Cancer. 128:2625-2634
Cancer-testis (CT) antigens comprise families of tumor-associated antigens that are immunogenic in patients with various cancers. Their restricted expression makes them attractive targets for immunotherapy. The aim of this study was to determine the